cetuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 4954 205923-56-4

Description:

MoleculeDescription

Synonyms:

  • cetuximab
  • cetuximab (genetical recombination)
  • erbitux
  • C-225
  • IMC-C225
A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 16, 2008 PMDA Merck
Feb. 12, 2004 FDA IMCLONE
June 29, 2004 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 539.54 24.50 137 14038 6217 90608055
Diarrhoea 232.02 24.50 474 13701 938716 89675556
Neutropenia 219.70 24.50 220 13955 224684 90389588
Malignant neoplasm progression 214.33 24.50 158 14017 106712 90507560
Mucosal inflammation 205.32 24.50 122 14053 57503 90556769
Dehydration 200.58 24.50 196 13979 194251 90420021
Serous retinal detachment 200.15 24.50 40 14135 594 90613678
Hypomagnesaemia 152.49 24.50 85 14090 35503 90578769
Disease progression 143.25 24.50 148 14027 156467 90457805
Paronychia 143.11 24.50 52 14123 7954 90606318
Skin toxicity 139.97 24.50 49 14126 6730 90607542
Vomiting 108.91 24.50 319 13856 787974 89826298
Rash 105.07 24.50 317 13858 795783 89818489
Nausea 104.19 24.50 394 13781 1109922 89504350
Pulmonary embolism 99.15 24.50 112 14063 130708 90483564
Neoplasm progression 98.70 24.50 70 14105 44416 90569856
Palmar-plantar erythrodysaesthesia syndrome 93.70 24.50 57 14118 27966 90586306
Radiation skin injury 80.08 24.50 21 14154 1079 90613193
Dermatitis 73.78 24.50 45 14130 22175 90592097
Colorectal cancer metastatic 70.51 24.50 18 14157 831 90613441
Hypokalaemia 69.81 24.50 94 14081 131022 90483250
Anaemia 68.06 24.50 162 14013 352640 90261632
Joint swelling 66.12 24.50 3 14172 503297 90110975
Chills 63.33 24.50 90 14085 131891 90482381
Skin fissures 61.16 24.50 39 14136 20770 90593502
Interstitial lung disease 60.56 24.50 67 14108 76338 90537934
Drug ineffective 57.53 24.50 80 14095 1384218 89230054
Metastases to lung 57.26 24.50 34 14141 15957 90598315
Pyrexia 54.77 24.50 226 13949 660259 89954013
Deep vein thrombosis 53.89 24.50 69 14106 91551 90522721
Thrombocytopenia 52.86 24.50 107 14068 208618 90405654
Arthralgia 51.46 24.50 29 14146 778493 89835779
Rash pustular 50.99 24.50 25 14150 8024 90606248
Neuropathy peripheral 50.97 24.50 83 14092 136887 90477385
Nasopharyngitis 48.73 24.50 4 14171 407100 90207172
Neutrophil count decreased 48.71 24.50 58 14117 71474 90542798
Ileus 48.59 24.50 31 14144 16515 90597757
Skin reaction 47.74 24.50 32 14143 18521 90595751
Melanocytic naevus 44.93 24.50 20 14155 5166 90609106
Abdominal discomfort 44.70 24.50 10 14165 477318 90136954
Hypocalcaemia 44.09 24.50 43 14132 42325 90571947
Febrile neutropenia 43.48 24.50 84 14091 158265 90456007
Haematotoxicity 43.19 24.50 26 14149 12509 90601763
Enteritis 42.41 24.50 24 14151 10297 90603975
Infusion related reaction 41.29 24.50 151 14024 416629 90197643
Decreased appetite 41.23 24.50 141 14034 376399 90237873
Weight increased 40.68 24.50 8 14167 417919 90196353
Leukopenia 40.16 24.50 63 14112 100647 90513625
Sinusitis 39.36 24.50 4 14171 343084 90271188
Drug intolerance 38.77 24.50 11 14164 447580 90166692
Intestinal obstruction 37.36 24.50 37 14138 37094 90577178
Sepsis 37.25 24.50 85 14090 179729 90434543
Metastases to liver 37.24 24.50 33 14142 28774 90585498
Neurotoxicity 36.91 24.50 29 14146 21438 90592834
Platelet count decreased 36.79 24.50 72 14103 136897 90477375
Hypertrichosis 35.62 24.50 12 14163 1467 90612805
Stomatitis 32.83 24.50 106 14069 274592 90339680
Asthenia 32.52 24.50 167 14008 533584 90080688
Dyspnoea 32.48 24.50 242 13933 880713 89733559
Therapeutic product effect decreased 32.46 24.50 3 14172 277568 90336704
Dry skin 32.24 24.50 53 14122 88020 90526252
Discomfort 31.98 24.50 3 14172 274332 90339940
Anaphylactic reaction 31.14 24.50 52 14123 87472 90526800
Abdominal pain 30.81 24.50 133 14042 395588 90218684
Bone marrow failure 30.38 24.50 31 14144 32190 90582082
Dysphagia 30.12 24.50 59 14116 112219 90502053
Trichomegaly 29.96 24.50 6 14169 90 90614182
Renal tubular disorder 29.82 24.50 13 14162 3194 90611078
Acne 29.78 24.50 29 14146 28478 90585794
K-ras gene mutation 29.70 24.50 5 14170 26 90614246
Drug hypersensitivity 29.54 24.50 18 14157 463591 90150681
Swelling 28.51 24.50 15 14160 419043 90195229
Immune thrombocytopenia 27.32 24.50 20 14155 13306 90600966
Anastomotic leak 27.07 24.50 8 14167 639 90613633
Second primary malignancy 26.94 24.50 18 14157 10360 90603912
Respiratory failure 26.78 24.50 58 14117 118360 90495912
Carcinoembryonic antigen increased 26.76 24.50 11 14164 2339 90611933
Multiple-drug resistance 26.45 24.50 16 14159 7760 90606512
Hyperchylomicronaemia 26.40 24.50 5 14170 55 90614217
Hydronephrosis 26.31 24.50 19 14156 12383 90601889
Hepatic enzyme increased 25.92 24.50 12 14163 360724 90253548
Pain 25.49 24.50 76 14099 996265 89618007
Endothelial dysfunction 25.25 24.50 6 14169 205 90614067
Stress cardiomyopathy 25.05 24.50 19 14156 13336 90600936
Haemolytic uraemic syndrome 24.86 24.50 11 14164 2800 90611472
Chemical burns of eye 24.61 24.50 5 14170 81 90614191

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 943.30 19.11 303 27596 7436 42586000
Infusion related reaction 456.82 19.11 352 27547 60454 42532982
Mucosal inflammation 411.02 19.11 304 27595 49070 42544366
Skin toxicity 321.55 19.11 131 27768 6418 42587018
Rash 288.15 19.11 588 27311 276366 42317070
Anaphylactic reaction 287.48 19.11 232 27667 42511 42550925
Hypomagnesaemia 281.93 19.11 195 27704 28293 42565143
Dehydration 277.45 19.11 399 27500 141368 42452068
Radiation skin injury 274.60 19.11 70 27829 715 42592721
Paronychia 229.20 19.11 91 27808 4164 42589272
Malignant neoplasm progression 222.06 19.11 312 27587 108088 42485348
Stomatitis 208.78 19.11 208 27691 50121 42543315
Serous retinal detachment 170.33 19.11 50 27849 894 42592542
Neutropenia 148.10 19.11 371 27528 199060 42394376
Palmar-plantar erythrodysaesthesia syndrome 132.52 19.11 109 27790 20473 42572963
Chills 127.33 19.11 224 27675 93842 42499594
Diarrhoea 115.16 19.11 599 27300 460250 42133186
Hypotension 114.22 19.11 399 27500 257232 42336204
Dysphagia 112.72 19.11 184 27715 72535 42520901
Drug ineffective 106.01 19.11 156 27743 630041 41963395
Hypersensitivity 105.31 19.11 178 27721 72192 42521244
Acne 102.23 19.11 79 27820 13565 42579871
Disease progression 96.92 19.11 258 27641 143398 42450038
Decreased appetite 96.90 19.11 312 27587 192825 42400611
Vomiting 95.08 19.11 408 27491 289315 42304121
Rash pustular 84.61 19.11 52 27847 6163 42587273
Flushing 80.75 19.11 110 27789 36918 42556518
Drug interaction 80.67 19.11 37 27862 266962 42326474
Pharyngeal inflammation 80.52 19.11 26 27873 646 42592790
Nausea 76.02 19.11 481 27418 396318 42197118
Product dose omission issue 70.43 19.11 9 27890 154356 42439080
Conjunctivitis 67.96 19.11 61 27838 12878 42580558
Skin reaction 66.63 19.11 47 27852 7020 42586416
Dermatitis 66.39 19.11 58 27841 11817 42581619
Condition aggravated 65.98 19.11 45 27854 260709 42332727
Erythema 64.99 19.11 187 27712 108606 42484830
Neoplasm progression 64.51 19.11 87 27812 28913 42564523
Pneumatosis intestinalis 62.76 19.11 39 27860 4713 42588723
Arthralgia 61.08 19.11 29 27870 205209 42388227
Pyrexia 55.71 19.11 444 27455 393598 42199838
Folliculitis 54.81 19.11 38 27861 5520 42587916
Fall 54.75 19.11 44 27855 234476 42358960
Interstitial lung disease 53.92 19.11 142 27757 78320 42515116
Neuropathy peripheral 53.20 19.11 167 27732 101686 42491750
Radiation mucositis 51.96 19.11 15 27884 252 42593184
Hypocalcaemia 51.72 19.11 80 27819 30093 42563343
Oxygen saturation decreased 51.70 19.11 124 27775 64563 42528873
Ileus 51.33 19.11 63 27836 19076 42574360
Pulse absent 50.39 19.11 38 27861 6289 42587147
Device related infection 50.00 19.11 64 27835 20215 42573221
COVID-19 49.98 19.11 8 27891 115940 42477496
Hepatic venous pressure gradient abnormal 49.73 19.11 10 27889 29 42593407
Pulmonary embolism 49.17 19.11 181 27718 119431 42474005
Neutrophil count decreased 47.95 19.11 119 27780 63296 42530140
Skin fissures 47.65 19.11 44 27855 9632 42583804
Thrombocytopenia 47.63 19.11 248 27651 190031 42403405
Leukopenia 47.07 19.11 131 27768 74615 42518821
Pain in extremity 45.22 19.11 21 27878 150583 42442853
Dyspnoea 43.37 19.11 461 27438 442160 42151276
Toxicity to various agents 43.08 19.11 52 27847 229084 42364352
Anaphylactic shock 42.63 19.11 64 27835 23453 42569983
Cardio-respiratory arrest 42.20 19.11 108 27791 58528 42534908
Oesophagitis 40.58 19.11 50 27849 15197 42578239
Gait disturbance 39.55 19.11 8 27891 97992 42495444
Product use in unapproved indication 38.93 19.11 38 27861 184418 42409018
Nasopharyngitis 38.04 19.11 5 27894 83991 42509445
Insomnia 37.86 19.11 15 27884 118238 42475198
Gastrointestinal toxicity 36.44 19.11 26 27873 3953 42589483
Tumour haemorrhage 36.17 19.11 25 27874 3613 42589823
Blood pressure immeasurable 36.14 19.11 16 27883 962 42592474
Weight increased 35.73 19.11 13 27886 107970 42485466
Onycholysis 35.72 19.11 16 27883 989 42592447
Portal venous gas 34.97 19.11 13 27886 496 42592940
Clostridial infection 34.75 19.11 25 27874 3849 42589587
Hospitalisation 34.70 19.11 4 27895 74326 42519110
Blood magnesium decreased 33.97 19.11 33 27866 7693 42585743
Urticaria 33.79 19.11 116 27783 73920 42519516
Proteus infection 33.69 19.11 17 27882 1373 42592063
White blood cell count decreased 32.66 19.11 151 27748 110245 42483191
Blood pressure decreased 32.62 19.11 98 27801 58234 42535202
Alopecia 32.38 19.11 64 27835 29212 42564224
Headache 31.24 19.11 69 27830 239300 42354136
Pneumonitis 31.22 19.11 78 27821 41640 42551796
Abdominal discomfort 30.66 19.11 6 27893 75249 42518187
Colorectal cancer metastatic 30.07 19.11 14 27885 947 42592489
Influenza 29.90 19.11 3 27896 62172 42531264
Metastases to lung 29.66 19.11 37 27862 11387 42582049
Febrile neutropenia 29.32 19.11 215 27684 185488 42407948
Peripheral ischaemia 29.08 19.11 28 27871 6457 42586979
Peripheral swelling 28.00 19.11 12 27887 90258 42503178
Nail disorder 27.98 19.11 18 27881 2309 42591127
Anxiety 27.93 19.11 22 27877 118538 42474898
Inappropriate schedule of product administration 27.81 19.11 14 27885 95888 42497548
Metastases to liver 27.57 19.11 43 27856 16283 42577153
Pruritus 26.69 19.11 213 27686 188558 42404878
Nail dystrophy 26.17 19.11 10 27889 412 42593024
Monocytopenia 26.06 19.11 7 27892 89 42593347
Haematotoxicity 26.03 19.11 34 27865 10951 42582485
Laryngeal oedema 25.31 19.11 21 27878 3987 42589449
Induration 25.23 19.11 13 27886 1097 42592339
Hypophagia 25.20 19.11 55 27844 26901 42566535
Intentional product misuse 25.08 19.11 5 27894 61895 42531541
Unresponsive to stimuli 24.86 19.11 60 27839 31343 42562093
Musculoskeletal stiffness 24.85 19.11 4 27895 57761 42535675
Coronary artery disease 24.80 19.11 3 27896 53717 42539719
Prothrombin level decreased 24.42 19.11 13 27886 1173 42592263
Overdose 24.21 19.11 20 27879 105244 42488192
Diabetes mellitus 24.04 19.11 5 27894 60082 42533354
Necrotising oesophagitis 23.90 19.11 12 27887 959 42592477
Depression 23.41 19.11 23 27876 111340 42482096
Metastases to lymph nodes 23.38 19.11 24 27875 5974 42587462
Hypokalaemia 23.38 19.11 101 27798 71620 42521816
Enteritis 23.36 19.11 32 27867 10784 42582652
Intentional product use issue 23.17 19.11 9 27890 71824 42521612
Dry skin 23.16 19.11 77 27822 48261 42545175
Joint swelling 22.82 19.11 8 27891 68014 42525422
Cardiac failure congestive 22.65 19.11 14 27885 85588 42507848
Embolism 22.14 19.11 28 27871 8735 42584701
Artery dissection 22.01 19.11 8 27891 286 42593150
Bronchospasm 21.84 19.11 34 27865 12851 42580585
Carcinoembryonic antigen increased 21.81 19.11 11 27888 887 42592549
Somnolence 21.57 19.11 37 27862 141068 42452368
Suicidal ideation 21.48 19.11 3 27896 48158 42545278
Loss of consciousness 21.43 19.11 118 27781 92236 42501200
Myalgia 21.18 19.11 19 27880 96061 42497375
Balance disorder 21.18 19.11 3 27896 47642 42545794
Macular oedema 21.09 19.11 18 27881 3551 42589885
Sepsis 21.01 19.11 211 27688 199123 42394313
Odynophagia 20.98 19.11 24 27875 6746 42586690
Pneumonia aspiration 20.72 19.11 76 27823 50002 42543434
Stridor 20.46 19.11 16 27883 2792 42590644
Memory impairment 20.46 19.11 4 27895 50218 42543218
Cerebral ischaemia 20.45 19.11 24 27875 6935 42586501
Pelvic sepsis 20.32 19.11 4 27895 10 42593426
Loss of personal independence in daily activities 20.23 19.11 4 27895 49812 42543624
Muscle spasms 20.22 19.11 16 27883 86028 42507408
Butterfly rash 20.09 19.11 6 27893 114 42593322
Abdominal compartment syndrome 19.67 19.11 11 27888 1094 42592342
Aspiration 19.65 19.11 39 27860 17847 42575589
Anaphylactoid reaction 19.61 19.11 16 27883 2967 42590469
Hypovolaemic shock 19.28 19.11 26 27873 8633 42584803
Mucosal infection 19.19 19.11 7 27892 253 42593183

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 1365.12 20.34 387 36642 12308 110539962
Mucosal inflammation 471.44 20.34 330 36699 95811 110456459
Skin toxicity 470.31 20.34 169 36860 11614 110540656
Hypomagnesaemia 448.32 20.34 269 36760 60101 110492169
Malignant neoplasm progression 423.56 20.34 397 36632 174170 110378100
Dehydration 406.95 20.34 484 36545 279027 110273243
Neutropenia 393.84 20.34 552 36477 374068 110178202
Serous retinal detachment 357.72 20.34 88 36941 1584 110550686
Paronychia 343.40 20.34 132 36897 10949 110541321
Radiation skin injury 329.54 20.34 82 36947 1550 110550720
Diarrhoea 307.25 20.34 955 36074 1138550 109413720
Anaphylactic reaction 256.19 20.34 249 36780 114051 110438219
Disease progression 228.81 20.34 341 36688 243693 110308577
Palmar-plantar erythrodysaesthesia syndrome 224.97 20.34 151 36878 40874 110511396
Chills 210.51 20.34 288 36741 190292 110361978
Rash 196.77 20.34 662 36367 820302 109731968
Infusion related reaction 187.88 20.34 402 36627 380760 110171510
Neuropathy peripheral 143.43 20.34 233 36796 179044 110373226
Neoplasm progression 143.29 20.34 140 36889 64455 110487815
Interstitial lung disease 141.02 20.34 202 36827 139132 110413138
Pulmonary embolism 137.87 20.34 253 36776 214221 110338049
Arthralgia 134.09 20.34 47 36982 779585 109772685
Thrombocytopenia 133.28 20.34 333 36696 348552 110203718
Decreased appetite 132.98 20.34 405 36624 475441 110076829
Dysphagia 131.61 20.34 206 36823 153394 110398876
Stomatitis 128.40 20.34 281 36748 269961 110282309
Vomiting 126.99 20.34 621 36408 910054 109642216
Rash pustular 118.66 20.34 66 36963 12763 110539507
Dermatitis 116.73 20.34 87 36942 27750 110524520
Hypotension 115.99 20.34 412 36617 523437 110028833
Joint swelling 114.33 20.34 9 37020 442836 110109434
Leukopenia 109.09 20.34 186 36843 148605 110403665
Nausea 107.21 20.34 743 36286 1234947 109317323
Pyrexia 106.73 20.34 586 36443 897679 109654591
Nasopharyngitis 101.82 20.34 8 37021 394353 110157917
Drug ineffective 99.04 20.34 228 36801 1520312 109031958
Metastases to lung 96.52 20.34 72 36957 22991 110529279
Ileus 96.49 20.34 81 36948 30648 110521622
Hypocalcaemia 96.14 20.34 114 36915 65252 110487018
Peripheral swelling 94.42 20.34 12 37017 404022 110148248
Febrile neutropenia 93.45 20.34 275 36754 316492 110235778
Pharyngeal inflammation 93.25 20.34 31 36998 1683 110550587
Skin fissures 92.76 20.34 72 36957 24386 110527884
Skin reaction 90.71 20.34 67 36962 21077 110531193
Acne 88.41 20.34 80 36949 33440 110518830
Colorectal cancer metastatic 87.49 20.34 29 37000 1560 110550710
Anaemia 86.96 20.34 388 36641 546698 110005572
Neutrophil count decreased 85.77 20.34 149 36880 120792 110431478
Abdominal discomfort 84.45 20.34 15 37014 393843 110158427
Weight increased 83.70 20.34 19 37010 419625 110132645
Hypokalaemia 82.39 20.34 186 36843 182262 110370008
Condition aggravated 75.42 20.34 81 36948 734755 109817515
Musculoskeletal stiffness 74.15 20.34 5 37024 279817 110272453
Enteritis 73.97 20.34 57 36972 19099 110533171
Drug interaction 73.34 20.34 38 36991 500145 110052125
Conjunctivitis 72.61 20.34 72 36957 33720 110518550
Headache 72.38 20.34 115 36914 882262 109670008
Sepsis 71.91 20.34 257 36772 327089 110225181
Metastases to liver 71.63 20.34 73 36956 35313 110516957
Flushing 70.33 20.34 126 36903 104610 110447660
White blood cell count decreased 68.42 20.34 200 36829 229190 110323080
Drug intolerance 67.24 20.34 26 37003 406486 110145784
Fall 67.08 20.34 62 36967 603420 109948850
Erythema 66.74 20.34 232 36797 291215 110261055
Sinusitis 66.49 20.34 10 37019 296678 110255592
Therapeutic product effect decreased 65.82 20.34 4 37025 244312 110307958
Product dose omission issue 65.29 20.34 14 37015 321768 110230502
Device related infection 64.95 20.34 73 36956 39446 110512824
Wound 62.67 20.34 4 37025 234433 110317837
Asthma 62.07 20.34 6 37023 250285 110301985
Glossodynia 61.77 20.34 3 37026 222001 110330269
Pain in extremity 61.65 20.34 44 36985 487074 110065196
Pulse absent 60.53 20.34 41 36988 11251 110541019
Tumour haemorrhage 59.76 20.34 31 36998 5214 110547056
Haematotoxicity 56.94 20.34 51 36978 21031 110531239
Contraindicated product administered 56.48 20.34 8 37021 248259 110304011
Oesophagitis 55.88 20.34 58 36971 28657 110523613
Melanocytic naevus 54.79 20.34 30 36999 5624 110546646
Sleep disorder 54.27 20.34 3 37026 198641 110353629
Radiation mucositis 54.20 20.34 14 37015 309 110551961
Hepatic enzyme increased 53.92 20.34 20 37009 320872 110231398
Pain 53.61 20.34 154 36875 954801 109597469
Dry skin 53.39 20.34 114 36915 107539 110444731
Deep vein thrombosis 52.74 20.34 133 36896 139754 110412516
Contusion 51.97 20.34 8 37021 233353 110318917
Pneumonitis 51.28 20.34 92 36937 76439 110475831
Discomfort 51.05 20.34 6 37023 214701 110337569
Intestinal obstruction 50.65 20.34 75 36954 53152 110499118
Drug hypersensitivity 50.02 20.34 47 36982 454043 110098227
Pericarditis 49.98 20.34 7 37022 219107 110333163
Intentional product use issue 49.85 20.34 11 37018 247895 110304375
Dyspnoea 49.62 20.34 577 36452 1106295 109445975
Swelling 49.48 20.34 28 37001 351013 110201257
Osteoarthritis 49.15 20.34 3 37026 182620 110369650
Pneumatosis intestinalis 48.19 20.34 32 36997 8497 110543773
Insomnia 47.70 20.34 31 36998 360559 110191711
Drug abuse 47.49 20.34 3 37026 177408 110374862
Neurotoxicity 46.83 20.34 64 36965 42143 110510127
Oxygen saturation decreased 45.95 20.34 136 36893 156846 110395424
Onycholysis 45.24 20.34 21 37008 2778 110549492
Gait disturbance 44.02 20.34 19 37010 278189 110274081
Product use in unapproved indication 43.98 20.34 51 36978 447326 110104944
COVID-19 43.36 20.34 14 37015 245046 110307224
Memory impairment 41.11 20.34 8 37021 196936 110355334
Treatment failure 40.69 20.34 21 37008 277213 110275057
Gastrointestinal toxicity 40.50 20.34 32 36997 11116 110541154
Gastrooesophageal reflux disease 40.46 20.34 6 37023 179970 110372300
Cardio-respiratory arrest 40.43 20.34 107 36922 115729 110436541
Blood magnesium decreased 40.01 20.34 41 36988 19955 110532315
Injury 39.64 20.34 6 37023 177259 110375011
Influenza 39.52 20.34 5 37024 169096 110383174
Small intestinal obstruction 39.04 20.34 51 36978 32162 110520108
Blood pressure immeasurable 38.61 20.34 18 37011 2405 110549865
Pneumonia aspiration 37.96 20.34 84 36945 81149 110471121
Migraine 37.95 20.34 6 37023 171646 110380624
Hypoaesthesia 37.65 20.34 30 36999 314193 110238077
Clostridial infection 36.47 20.34 24 37005 6278 110545992
Bone marrow failure 35.55 20.34 67 36962 57781 110494489
Abdominal pain 34.90 20.34 292 36737 512697 110039573
Anaphylactic shock 34.57 20.34 62 36967 51484 110500786
Macular oedema 34.29 20.34 24 37005 6942 110545328
Cerebral ischaemia 34.12 20.34 30 36999 12074 110540196
Blood pressure decreased 33.94 20.34 100 36929 114991 110437279
Hospitalisation 33.82 20.34 4 37025 142489 110409781
Bronchospasm 33.77 20.34 46 36983 30193 110522077
Subileus 33.62 20.34 23 37006 6414 110545856
Respiratory failure 33.55 20.34 152 36877 215180 110337090
Duodenal ulcer perforation 33.54 20.34 9 37020 177691 110374579
Carcinoembryonic antigen increased 33.07 20.34 17 37012 2807 110549463
Proteus infection 33.04 20.34 17 37012 2811 110549459
K-ras gene mutation 32.53 20.34 7 37022 67 110552203
Bursitis 32.50 20.34 3 37026 129915 110422355
Nail dystrophy 32.31 20.34 13 37016 1215 110551055
Blister 32.22 20.34 18 37011 227358 110324912
Liver injury 31.63 20.34 6 37023 150407 110401863
Loss of personal independence in daily activities 31.51 20.34 6 37023 150014 110402256
Depression 31.36 20.34 36 36993 317299 110234971
Anxiety 31.11 20.34 42 36987 345036 110207234
Laryngeal oedema 31.09 20.34 26 37003 9781 110542489
Intentional product misuse 30.89 20.34 4 37025 132900 110419370
Arthritis 30.67 20.34 9 37020 167577 110384693
Hyperbilirubinaemia 30.31 20.34 44 36985 30627 110521643
Impaired healing 30.22 20.34 14 37015 196703 110355567
Embolism 30.08 20.34 32 36997 16257 110536013
Platelet count decreased 29.67 20.34 154 36875 230289 110321981
Gait inability 29.63 20.34 5 37024 136371 110415899
Toxicity to various agents 29.53 20.34 74 36955 480481 110071789
Respiratory distress 28.62 20.34 68 36961 68806 110483464
Peripheral ischaemia 28.39 20.34 26 37003 11032 110541238
Lower respiratory tract infection 28.13 20.34 24 37005 243082 110309188
Aortic thrombosis 28.07 20.34 14 37015 2169 110550101
Hypersensitivity 28.01 20.34 231 36798 403767 110148503
Venous thrombosis 27.90 20.34 23 37006 8482 110543788
Trichomegaly 27.66 20.34 7 37022 142 110552128
Prothrombin level decreased 27.46 20.34 13 37016 1797 110550473
Overdose 27.15 20.34 23 37006 233771 110318499
Periorbital disorder 26.88 20.34 6 37023 69 110552201
Staphylococcal infection 26.87 20.34 67 36962 69877 110482393
Night sweats 26.81 20.34 6 37023 133977 110418293
Abdominal compartment syndrome 26.69 20.34 13 37016 1914 110550356
Myelosuppression 25.96 20.34 80 36949 94260 110458010
Necrotising oesophagitis 25.85 20.34 12 37017 1588 110550682
Endothelial dysfunction 25.84 20.34 8 37021 345 110551925
Road traffic accident 25.52 20.34 3 37026 107395 110444875
Cutaneous symptom 25.49 20.34 10 37019 875 110551395
Lymphopenia 25.27 20.34 47 36982 40123 110512147
Monocytopenia 25.15 20.34 7 37022 207 110552063
Septic shock 25.13 20.34 112 36917 157416 110394854
Loss of consciousness 25.13 20.34 131 36898 196175 110356095
Aspiration 24.80 20.34 40 36989 30493 110521777
Bronchitis 24.39 20.34 11 37018 157021 110395249
Skin squamous cell carcinoma recurrent 24.38 20.34 6 37023 108 110552162
Haemolytic uraemic syndrome 24.13 20.34 17 37012 4968 110547302
Hypophagia 24.11 20.34 54 36975 52572 110499698
Second primary malignancy 24.09 20.34 30 36999 18038 110534232
Induration 24.05 20.34 13 37016 2376 110549894
Artery dissection 23.91 20.34 8 37021 443 110551827
Macular detachment 23.91 20.34 7 37022 249 110552021
Balance disorder 23.77 20.34 5 37024 116555 110435715
Hypoalbuminaemia 23.59 20.34 38 36991 28936 110523334
Metastases to lymph nodes 23.39 20.34 27 37002 15005 110537265
Photosensitivity reaction 22.83 20.34 35 36994 25554 110526716
Abdominal pain upper 22.83 20.34 52 36977 349059 110203211
Ill-defined disorder 22.83 20.34 12 37017 156841 110395429
Nasal congestion 22.74 20.34 3 37026 98279 110453991
Inappropriate schedule of product administration 22.48 20.34 21 37008 203616 110348654
Hydronephrosis 22.42 20.34 31 36998 20634 110531636
Gastrointestinal perforation 22.06 20.34 19 37010 7437 110544833
Hyperchylomicronaemia 22.06 20.34 5 37024 62 110552208
Squamous cell carcinoma of head and neck 22.05 20.34 7 37022 328 110551942
Hypertrichosis 21.68 20.34 11 37018 1767 110550503
Tachycardia 21.68 20.34 140 36889 226505 110325765
Electrolyte imbalance 21.66 20.34 42 36987 36986 110515284
Fluid retention 21.53 20.34 3 37026 94304 110457966
Eyelid oedema 21.41 20.34 26 37003 15236 110537034
Ileal perforation 21.07 20.34 10 37019 1390 110550880
Sciatica 20.95 20.34 3 37026 92396 110459874
Lymphangiosis carcinomatosa 20.87 20.34 12 37017 2470 110549800
Acute respiratory distress syndrome 20.48 20.34 51 36978 53147 110499123
Performance status decreased 20.46 20.34 18 37011 7248 110545022

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FE01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA MoA N0000020010 HER1 Antagonists
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000175664 Epidermal Growth Factor Receptor Antagonist
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors 2 drugs
necitumumabpanitumumab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Head and neck cancer indication 255055008 DOID:11934
Squamous cell carcinoma of mouth indication 307502000
Rectal cancer with wild-type RAS indication 363351006 DOID:1993
Malignant tumor of colon indication 363406005 DOID:219
Squamous cell carcinoma of larynx indication 405822008
Squamous cell carcinoma of pharynx indication 408649007
Squamous cell carcinoma of nose indication 448930008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Epidermal growth factor receptor Kinase ANTIBODY BINDING Kd 9.41 IUPHAR DRUG LABEL

External reference:

IDSource
D03455 KEGG_DRUG
4021419 VUID
N0000148833 NUI
4021419 VANDF
CHEBI:749550 CHEBI
CHEMBL1201577 ChEMBL_ID
6882 IUPHAR_LIGAND_ID
DB00002 DRUGBANK_ID
318341 RXNORM
17947 MMSL
48970 MMSL
d05101 MMSL
008568 NDDF
409400001 SNOMEDCT_US
409401002 SNOMEDCT_US
C0995188 UMLSCUI
D000068818 MESH_DESCRIPTOR_UI
7906 INN_ID
85668777 PUBCHEM_CID
PQX0D8J21J UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ERBITUX HUMAN PRESCRIPTION DRUG LABEL 1 66733-948 SOLUTION 2 mg INTRAVENOUS BLA 29 sections
ERBITUX HUMAN PRESCRIPTION DRUG LABEL 1 66733-958 SOLUTION 2 mg INTRAVENOUS BLA 29 sections